

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims

Non-elected claims 1-11 and 14-17 have been cancelled.

Claims 12 and 13 have been amended as follows:

12. (Amended) A method for stimulating an immune response in a patient, comprising administering to the patient a composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising a polypeptide selected from the group consisting of:

(a) a polypeptide encoded by the polynucleotide set forth in SEQ ID NO:1788;

(b) a polypeptide comprising the amino acid sequences set forth in SEQ ID NO:1789; and

(c) polypeptides comprising an amino acid sequence having at least 90% identity to the sequence set forth in SEQ ID NO:1789.

~~of claim 11.~~

13. (Amended) A method for the treatment of a cancer in a patient, comprising administering to the patient a composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising a polypeptide selected from the group consisting of:

(a) a polypeptide encoded by the polynucleotide set forth in SEQ ID NO:1788;

(b) a polypeptide comprising the amino acid sequences set forth in SEQ ID NO:1789; and

(c) polypeptides comprising an amino acid sequence having at least 90% identity to the sequence set forth in SEQ ID NO:1789.

~~of claim 11.~~